Trial Profile

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
Indications Influenza virus infections
Focus Pharmacodynamics
Acronyms PIVOT

Most Recent Events

24 Sep 2021 Planned End Date changed from 1 Sep 2022 to 1 Dec 2026.
24 Sep 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Dec 2025
14 May 2020 Results comparing reactogenicity of influenza vaccines and analysing antibody titer at day 0 and day 30 in subset (n=800) of participants, published in the Journal of Infectious Diseases.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com